$CHRO
Channel Therapeutics Corp Stock $chro

$chro Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000175392624001423 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$727.2K
YoY Change			169.23%
% of Gross Profit
Research & Development	$414.6K	$12.96K	$50.00K
YoY Change	744.48%	-74.09%	87.97%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.048M	$1.764M	$777.2K
YoY Change	58.58%	126.98%	161.95%
Operating Profit	-$2.048M	-$1.764M	-$777.2K
YoY Change	58.57%	126.99%
Interest Expense			-$176.2K
YoY Change			371.12%
% of Operating Profit
Other Income/Expense, Net	$353.7K	-$7.533K	-$176.2K
YoY Change	-372.05%	-95.72%
Pretax Income	-$1.695M	-$1.772M	-$953.4K
YoY Change	19.2%	85.82%	185.36%
Income Tax
% Of Pretax Income
Net Earnings	-$1.695M	-$1.772M	-$953.4K
YoY Change	19.2%	85.82%	185.36%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.29	-$0.31	-$0.95
Diluted Earnings Per Share			-$0.17
COMMON SHARES
Basic Shares Outstanding	5.767M shares	5.878M shares	1.003M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments			$82.00K
YoY Change			4000.0%
Cash & Equivalents	$1.255M	$2.405M	$81.89K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$94.59K	$158.1K
Receivables
Other Receivables
Total Short-Term Assets	$2.140M	$2.604M	$82.00K
YoY Change	9203.86%	3075.12%	4000.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$2.140M	$2.604M	$82.00K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$2.140M	$2.604M	$82.00K
YoY Change	9203.86%	3075.12%	4000.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$3.547M
YoY Change			42.97%
Accrued Expenses	$308.00	$363.4K	$452.0K
YoY Change	-99.95%	-19.6%	1002.44%
Deferred Revenue
YoY Change
Short-Term Debt			$983.0K
YoY Change			173.06%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.567M	$2.786M	$4.983M
YoY Change	-39.81%	-44.09%	72.9%
LONG-TERM LIABILITIES
Long-Term Debt			$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities			$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.567M	$2.786M	$4.983M
Total Long-Term Liabilities			$0.00
Total Liabilities	$3.567M	$2.786M	$4.983M
YoY Change	-39.81%	-44.09%	15.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.55M	-$17.85M
YoY Change
Common Stock	$583.00	$584.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.427M	-$182.5K	-$4.901M
YoY Change
Total Liabilities & Shareholders Equity	$2.140M	$2.604M	$82.00K
YoY Change	9203.86%	3075.12%	4000.0%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.695M	-$1.772M	-$953.4K
YoY Change	19.2%	85.82%	185.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities			-$193.6K
YoY Change			-33.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			226.9K
YoY Change			-22.77%
NET CHANGE
Cash From Operating Activities			-193.6K
Cash From Investing Activities
Cash From Financing Activities			226.9K
Net Change In Cash			33.30K
YoY Change			1287.5%
FREE CASH FLOW
Cash From Operating Activities			-$193.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Assets Current AssetsCurrent	96391	usd
CY2024Q2	us-gaap	Assets Assets	2603600	usd
CY2023Q4	us-gaap	Assets Assets	96391	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	835408	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4620925	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	645947	usd
CY2023Q4	us-gaap	Bridge Loan BridgeLoan	316324	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	131868	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	750082	usd
CY2023Q4	chro	Due To Chromocell Corporation DueToChromocellCorporation	5386	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2786121	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6540943	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2786121	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6540943	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7533	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2603600	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	363429	usd
CY2024Q2	us-gaap	Other Loans Payable OtherLoansPayable	1455416	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	584	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17670493	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17853598	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2603600	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2023Q4	us-gaap	Cash And Due From Banks CashAndDueFromBanks		usd
CY2024Q2	us-gaap	Bridge Loan BridgeLoan		usd
CY2024Q2	chro	Due To Chromocell Corporation DueToChromocellCorporation		usd
CY2023Q2	us-gaap	Other Income OtherIncome		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q1	chro	Stock Issued During Period Value Standby Agreement StockIssuedDuringPeriodValueStandbyAgreement		usd
	chro	Issuance Cost From Shares Issued On Extension Of Bridge Loan IssuanceCostFromSharesIssuedOnExtensionOfBridgeLoan		usd
	chro	Due From Chromocell Corporation DueFromChromocellCorporation		usd
	chro	Prepaid Prepaid		usd
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	chro	Conversion Of Notes ConversionOfNotes		usd
	chro	Transfer Of Liabilities To Chromocell Corp For Preferred Stock TransferOfLiabilitiesToChromocellCorpForPreferredStock		usd
	us-gaap	Net Income Loss NetIncomeLoss	-4333949	usd
CY2024Q2	us-gaap	Cash Cash	2405098	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6540943	usd
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P9Y0M29D
	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingLife	P10Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q2	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P9Y7M17D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y7M10D
CY2022Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P9Y9M3D
	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingLife	P10Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q2	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P9Y6M25D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y5M12D
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedOptionsForfeitedNumberOfShares		shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Warrants Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWarrantsForfeitedWeightedAverageGrantDateFairValue
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedOptionsForfeitedNumberOfShares		shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Warrants Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWarrantsForfeitedWeightedAverageGrantDateFairValue
	chro	Weighted Average Period For The Unamortized Stock Compensation WeightedAveragePeriodForTheUnamortizedStockCompensation	P2Y1M9D
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber		shares
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice
	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Grants In Period Weighted Average Remaining Life ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageRemainingLife	P4Y10M17D
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExpirationsInPeriod		shares
	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsExpirationsInPeriodWeightedAverageExercisePrice
	chro	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised		shares
	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q2	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingLife	P4Y5M16D
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1	P4Y5M16D
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber		shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Warrants Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWarrantsForfeitedNumberOfShares		shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2024Q2	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedNumberOfShares		shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2023Q4	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Rs Us Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardRSUsNonvestedNumberOfShares		shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Rs Us Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardRSUsNonvestedWeightedAverageGrantDateFairValue
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Rs Us Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRSUsVestedNumberOfShares		shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Rs Usvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardRSUsvestedWeightedAverageGrantDateFairValue
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Rs Us Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRSUsForfeitedNumberOfShares		shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Rs Us Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRSUsForfeitedWeightedAverageGrantDateFairValue
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5766704	shares
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2023Q4	us-gaap	Cash Cash	96391	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	158102	usd
CY2024Q2	us-gaap	Cash And Due From Banks CashAndDueFromBanks	40400	usd
CY2023Q4	us-gaap	Other Loans Payable OtherLoansPayable	202279	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5823166	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	391	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7074646	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13519649	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-182521	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6444552	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96391	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1209874	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	537876	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12955	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49955	usd
CY2024Q2	us-gaap	Professional Fees ProfessionalFees	541257	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	189329	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1764086	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	777160	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1764086	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-777160	usd
CY2024Q2	chro	Interest Expense On Promissory Note Related Party InterestExpenseOnPromissoryNoteRelatedParty	11060	usd
CY2023Q2	chro	Interest Expense On Promissory Note Related Party InterestExpenseOnPromissoryNoteRelatedParty	176187	usd
CY2024Q2	us-gaap	Other Income OtherIncome	3527	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-176187	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-635881	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-228165	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1771619	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-953347	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4333949	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1919908	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1771619	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-953347	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4333949	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1919908	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5773708	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1002779	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5232349	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1056646	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3706537	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	272221	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-966561	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4440877	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	327338	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	126000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-953347	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4900886	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6444552	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	292552	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	447779	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	5972000	usd
CY2024Q1	chro	Stock Issued During Period Value Recission Of Common Stock StockIssuedDuringPeriodValueRecissionOfCommonStock	-91512	usd
CY2024Q1	chro	Stock Issued During Period Value Transfer Of Liabilities To Chromocell Corp.For Preferred C Shares StockIssuedDuringPeriodValueTransferOfLiabilitiesToChromocellCorp.ForPreferredCShares	2153363	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1362821	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2562330	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1130120	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	366503	usd
CY2024Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	13975	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	78500	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1771619	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-182521	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4333949	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1919908	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	605630	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	49122	usd
	chro	Issuance Cost From Shares Issued On Extension Of Bridge Loan IssuanceCostFromSharesIssuedOnExtensionOfBridgeLoan	126000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	751530	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	599559	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1481113	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	548297	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-282518	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	229941	usd
	chro	Due From Chromocell Corporation DueFromChromocellCorporation	-45786	usd
	chro	Prepaid Prepaid	-158102	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4944308	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-366989	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1455416	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	90157	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	131868	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	303651	usd
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-214757	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5972000	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	91512	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7253015	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	393808	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2308707	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	26819	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96391	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55074	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2405098	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81893	usd
	chro	Debt Discount From Shares Issued On Extension Of Bridge Loan DebtDiscountFromSharesIssuedOnExtensionOfBridgeLoan	447779	usd
	chro	Debt Discount From Shares Issued On Extension Of Bridge Loan DebtDiscountFromSharesIssuedOnExtensionOfBridgeLoan	126000	usd
	chro	Conversion Of Notes ConversionOfNotes	1362821	usd
	chro	Transfer Of Liabilities To Chromocell Corp For Preferred Stock TransferOfLiabilitiesToChromocellCorpForPreferredStock	2153362	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zrQKt5VL6Pyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 1 – <span id="xdx_824_zsIHwYnK7NJ3">ORGANIZATION AND NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Company Background </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Chromocell Therapeutics Corporation (“Chromocell” or the “Company”) was incorporated in the State of Delaware on March 19, 2021. On August 10, 2022, the Company entered into that certain Contribution Agreement (the “Contribution Agreement”) with Chromocell Corporation, a Delaware corporation (“Chromocell Holdings”), pursuant to which, effective July 12, 2022 (the “Contribution Date”), Chromocell Holdings contributed all assets and liabilities related to Chromocell Holdings’ historical therapeutic business, including all patents, pre-clinical and Phase I study results and data, and trade secrets related to the CC8464 compound to the Company. (See Note 4)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. The Company’s clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain receptor in human physiology. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”). The Company’s goal is to develop a novel and proprietary class of NaV blockers that target the body’s peripheral nervous system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has formally launched two programs developing pain treatment therapeutics, both based on the same proprietary molecule, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Neuropathic Pain</span>: CC8464 is being developed to address certain types of neuropathic pain. The chemical characteristics of CC8464 restrict its entry into the CNS and limit its effect to the NaV1.7 receptors in the peripheral nervous system, which consists of the nerves outside the brain and spinal cord. Activation of other receptors in the CNS can result in side effects, including addiction and other centrally mediated adverse effects. Since CC8464 is designed to not penetrate the CNS it is highly unlikely to produce CNS mediated side effects including euphoria or addiction. Based on its characteristics, preclinical studies (described below) and the Phase 1 studies the Company has completed to date, the Company believes that CC8464, if approved, could become an attractive option for both patients and physicians as a treatment for moderate-to-severe pain in EM and iSFN.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Eye Pain</span>: Based on the same proprietary molecule as CC8464, the Company’s newly launched program, titled CT2000, is for the potential treatment of both acute and chronic eye pain. NaV1.7 receptor is present on the cornea, making it a viable biological target for treating eye pain. Eye pain may occur with various conditions, including severe dry eye disease, trauma and surgery. Existing therapies for eye pain (such as steroids, topical non-steroidal anti-inflammatory agents, lubricants, local anesthetics) are limited in their effectiveness and/or limited in the duration that they may be prescribed because of safety issues. The Company intends to explore the viability of developing CT2000 as a topical agent for the relief of eye pain. A potential advantage of this approach is that topical administration of CT2000 is unlikely to lead to any hypersensitivity or skin reactions, like what was noted with systemic administration of CC8464, because the systemic absorption from a topical administration would be extremely limited. The Company has commenced development of a topical ophthalmic formulation of CT2000 that would initially be evaluated for ophthalmic toxicology and then followed by a POC trial in patients. The Company expects the trials for this ophthalmic formulation of CT2000 to start in 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may further expand its pipeline with other internal or external compounds in the future, but all other internally discovered compounds are pre-clinical and no commercial discussions about in-licensing have been initiated to date, other than as disclosed in this quarterly report with respect to the licensing of the certain spray formulations from Benuvia Operations LLC (“Benuvia”), entered into on December 23, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company has a limited operating history and has not generated revenue from its intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include changes in the biotechnology regulatory environment, technological advances that render the Company’s technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On February 21, 2024, the Company completed the initial public offering of its Common Stock (the “IPO”) and issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20240219__20240221__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zSBzaOLzIHH5" title="Offering shares of common stock">1,100,000</span> shares of its Common Stock at a price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20240221__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRmaJOIQForg" title="Common stock, per share">6.00</span> per share. The aggregate net proceeds from the IPO were approximately $<span id="xdx_908_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_dm_c20240219__20240221__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zSYH6xtezTR" title="Net proceeds">5.7 million</span> after deducting $<span id="xdx_90A_eus-gaap--OtherUnderwritingExpense_dm_c20240219__20240221__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTKutCEN67vg" title="Offering expenses">0.9 million</span> in underwriting discounts and commissions and offering expenses.</span></p>
CY2024Q2	chro	Working Capital Deficit WorkingCapitalDeficit	200000	usd
CY2024Q2	us-gaap	Cash Cash	2400000	usd
CY2024Q2	chro	Working Capital Deficit WorkingCapitalDeficit	200000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100000	usd
CY2023Q4	chro	Working Capital Deficit WorkingCapitalDeficit	6400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zw7FVosvc123" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_866_zwhfVX9nwaF7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the valuation of deferred income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	chro	Disaggregation Of R And D Expenses DisaggregationOfRAndDExpenses	<p id="xdx_897_ecustom--DisaggregationOfRAndDExpenses_z9jim6Ibpmff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span><span id="xdx_8B3_zWaCJ2MPgcrc">Below is a disaggregation of R&D expenses:</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Consultant</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630__srt--ProductOrServiceAxis__custom--ConsultantMember_zzkVFWxoGClj" style="width: 10%; text-align: right" title="Research and development expense">107,357</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630__srt--ProductOrServiceAxis__custom--ConsultantMember_za5KYtA92g9e" style="width: 10%; text-align: right" title="Research and development expense">16,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__srt--ProductOrServiceAxis__custom--ConsultantMember_z2NPwTbU3qP5" style="width: 10%; text-align: right" title="Research and development expense">137,390</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__srt--ProductOrServiceAxis__custom--ConsultantMember_zUsqqCPLf5Tj" style="width: 10%; text-align: right" title="Research and development expense">23,300</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab Materials</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630__srt--ProductOrServiceAxis__custom--LabMaterialsMember_z7lsemiEUxci" style="text-align: right" title="Research and development expense">1,452</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630__srt--ProductOrServiceAxis__custom--LabMaterialsMember_zOGgoNX7lsIh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__srt--ProductOrServiceAxis__custom--LabMaterialsMember_z2hTgPOjkPma" style="text-align: right">1,452</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__srt--ProductOrServiceAxis__custom--LabMaterialsMember_zNsd49pWO1h8" style="text-align: right" title="Research and development expense"><span style="-sec-ix-hidden: xdx2ixbrl0619">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lab Cell Storage</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zD5n4k0h7117" style="text-align: right" title="Research and development expense">27,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zbMcdXcv9HOi" style="text-align: right">7,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zleDqEslNvp9" style="text-align: right">51,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zsoQm1wUl2t" style="text-align: right" title="Research and development expense">17,753</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chemistry Manufacturing and Controls (“CMC”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_iN_di_c20240401__20240630__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_zktuBuhPVnul" style="text-align: right" title="Research and development expense">(133,780</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_zDVSLXH1pwcd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_zkjMDsBzkWn5" style="text-align: right">169,617</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_z9prSKDBTwk" style="text-align: right" title="Research and development expense"><span style="-sec-ix-hidden: xdx2ixbrl0631">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">IP Services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630__srt--ProductOrServiceAxis__custom--IPServicesMember_ztqOiUbn1Nr9" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">10,654</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630__srt--ProductOrServiceAxis__custom--IPServicesMember_zdcuVgrZzXM8" style="border-bottom: Black 1pt solid; text-align: right">35,402</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__srt--ProductOrServiceAxis__custom--IPServicesMember_zzZj4Te1Az9b" style="border-bottom: Black 1pt solid; text-align: right">119,704</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__srt--ProductOrServiceAxis__custom--IPServicesMember_zD6izYiOBNQ6" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">195,019</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_zGaB7oO1Adod" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">12,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630_zZYtmESaZJG8" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">49,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630_zUNgCTLpoCmj" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">479,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630_z73fl2lZRk2h" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">236,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12955	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49955	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	479561	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	236072	usd
CY2022Q4	chro	Director Note Description DirectorNoteDescription	the Company and Mr. Todd Davis, one of the Company’s directors, entered into the Director Note for $175,000. The Director Note has an original issuance discount of $75,000, and matures on December 31, 2023, or, if earlier to occur, upon the closing of an underwritten offering of securities resulting in at least $15 million in gross proceeds. On December 28, 2023, the Company entered into an amendment to the Director Note, which extended the maturity date to February 29, 2024. On February 21, 2024, the principal and accrued interest on this note converted into 29,167 shares of the Company’s Common Stock.
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	75000	usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15000000	usd
CY2024Q2	chro	Due To Receivable DueToReceivable	40400	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	131868	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	895	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	450000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	150000	usd
CY2022Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.50	pure
CY2022Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-02-03
	us-gaap	Interest Expense Debt InterestExpenseDebt	14370	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	135630	usd
CY2023Q1	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	the Investor Note was amended. The maturity date was extended from its original due date of February 3, 2023 to May 15, 2023, in return for the Company agreeing to pay 2% per month in accrued interest and the third party agreeing to settle its outstanding debt, including accrued interests in shares of Common Stock at the IPO.
CY2023Q2	us-gaap	Debt Conversion Description DebtConversionDescription	(ii) in consideration therefor, issued to such holder 50,000 shares of Common Stock. The Company determined that this extension qualified as a modification of the Investor Note rather than an extinguishment. The Company recorded an expense of $126,000 from the issuance of the 556 shares of Common Stock based on a share price of $22.68. The $22.68 share price was based on a third-party valuation of the Company’s Common Stock, with certain adjustments as set forth below in detail in Note 7 – Stockholders’ Equity.
CY2024Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	the Company effected a 9-for-1 reverse stock split. All share and per share amounts have been retrospectively adjusted for the reverse stock split.
CY2023Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	1203704	shares
	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	(ii) in consideration therefor, the Company would issue upon close of the IPO, and regardless of whether the Company would have issued any shares of Series B Preferred Stock, an aggregate of 4,167 shares (such shares, the “Standby Shares”) of Common Stock to the Standby Investor (such agreement, the “Series B Securities Purchase Agreement”). In addition, pursuant to the Series B Securities Purchase Agreement, the Company was required to file a registration statement within 180 calendar days after consummation of the IPO, providing for the resale of the Standby Shares and shares of Common Stock issuable upon conversion of the Series B Preferred Stock, if issued.
CY2024Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	50000	shares
CY2024Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	7500	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	6462	shares
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44800000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1187302	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	37.71
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44800000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1187302	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	37.71
CY2022Q3	chro	Illiquidity Discount IlliquidityDiscount	0.20	pure
CY2022Q3	chro	Minority Discount MinorityDiscount	0.20	pure
CY2022Q3	chro	Fair Value Of Common Stock Per Share FairValueOfCommonStockPerShare	22.68
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	197560	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	634000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	11111	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.68
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	820449	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.159
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	116612	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.68
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	50002	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	158670	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	11111	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.68
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	197560	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	34724	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.68
CY2023Q4	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedNumberOfShares	113429	shares
CY2023Q4	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedWeightedAverageGrantDateFairValue	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	634000	shares
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageGrantDateFairValue	1.30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	43592	shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsVestedWeightedAverageGrantDateFairValue	22.68
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	703837	shares
CY2024Q2	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedWeightedAverageGrantDateFairValue	3.42
CY2022Q4	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedNumberOfShares	45556	shares
CY2022Q4	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedWeightedAverageGrantDateFairValue	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	158670	shares
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageGrantDateFairValue	22.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	30232	shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsVestedWeightedAverageGrantDateFairValue	22.68
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	173994	shares
CY2023Q2	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedWeightedAverageGrantDateFairValue	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	634000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	158670	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	1.30
	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue1	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12680	usd
CY2024Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	366503	usd
CY2023Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	327338	usd
	chro	General And Administrative Expenses GeneralAndAdministrativeExpenses	659055	usd
	chro	General And Administrative Expenses GeneralAndAdministrativeExpenses	599559	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	2057817	usd
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodGross	55000	shares
	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice	7.50
CY2024Q2	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber	55000	shares
CY2024Q2	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice	7.50
CY2024Q2	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber	55000	shares
CY2024Q2	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice	7.50
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodGross	55000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.50
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsVestedNumberOfShares	55000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	7.50
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriod	55000	shares
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriod	0	shares
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodGrantDateIntrinsicValue	7.50
	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	the Company issued warrants to purchase up to 55,000 shares of Common Stock to the representative of the underwriters of the IPO (the “Representative”). These warrants have an exercise price of $7.50, have a cashless exercise provision, are exercisable 180 days following the commencement of sales of the shares of Common Stock of the IPO and have an expiration date of February 21, 2029
	chro	Share Based Compensation Arrangement By Share Based Payment Award Rs Us Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantsInPeriodGross	257993	shares
	chro	Share Based Compensation Arrangement By Share Based Payment Award Rs Us Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantsInPeriodWeightedAverageGrantDateFairValue	1.30
CY2024Q2	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Rs Us Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardRSUsNonvestedNumberOfShares	257993	shares
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Rs Us Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardRSUsNonvestedWeightedAverageGrantDateFairValue	1.30
	chro	Sharebased Compensation Arrangement By Sharebased Payment Rs Us Warrants Nonvested Period SharebasedCompensationArrangementBySharebasedPaymentRSUsWarrantsNonvestedPeriod	257993	shares
	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Rs Us Nonvested Period SharebasedCompensationArrangementBySharebasedPaymentAwardRSUsNonvestedPeriod	0	shares
	chro	Share Based Compensation Arrangement By Share Based Payment Award Rs Us Grants Non Vested In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantsNonVestedInPeriodGrantDateIntrinsicValue	1.30
CY2024Q2	chro	Adjustment For Amortization1 AdjustmentForAmortization1	13975	usd
CY2023Q2	chro	Adjustment For Amortization1 AdjustmentForAmortization1	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	13975	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2024Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	479169	usd
CY2024Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	479169	usd
CY2024Q2	us-gaap	Other Expenses OtherExpenses	363091	usd
CY2024Q2	us-gaap	Loss Contingency Allegations LossContingencyAllegations	pay an initial lump-sum payment of $10,000 toward outstanding rent and provide a copy of its Registration Statement on Form S-1 for the Company’s IPO (the “Registration Statement”) and (iii) make a final one-time lump sum payment to the EDA of $510,701 to satisfy Chromocell Holdings’ outstanding rent and additional rent obligations within 90 days of Chromocell Holdings’ executing the Settlement Agreement or within 15 days of Chromocell Holdings’ IPO, whichever was the first to occur. The complaint alleges Chromocell Holdings’ breach of each of these provisions of the Settlement Agreement and seeks a judgment for the entire amount allegedly due and owing as of September 12, 2023 ($510,701), compensatory damages, pre-judgment interest, attorney’s fees, costs of suit and such other and further relief as the court deems just and proper

Files In Submission

Name	View Source	Status
0001753926-24-001423-index-headers.html	Edgar Link	pending
0001753926-24-001423-index.html	Edgar Link	pending
0001753926-24-001423.txt	Edgar Link	pending
0001753926-24-001423-xbrl.zip	Edgar Link	pending
chro-20240630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g084373_10q.htm	Edgar Link	pending
g084373_ex31-1.htm	Edgar Link	pending
g084373_ex32-1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
chro-20240630_def.xml	Edgar Link	unprocessable
chro-20240630_lab.xml	Edgar Link	unprocessable
chro-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
g084373_10q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
chro-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHRO
Channel Therapeutics Corp Stock $chro

2024 Q3 Form 10-Q Financial Statement

#000175392624001423 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRO Channel Therapeutics Corp Stock $chro

2024 Q3 Form 10-Q Financial Statement

#000175392624001423 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRO
Channel Therapeutics Corp Stock $chro